📣 VC round data is live. Check it out!
- Public Comps
- Twist Bioscience
Twist Bioscience Valuation Multiples
Discover Twist Bioscience's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like BillionToOne, Celcuity, 10x Genomics, Veracyte and more.
Twist Bioscience Overview
About Twist Bioscience
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company’s proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Founded
2013
HQ

Employees
979
Website
Financials (LTM)
EV
$4B
Valuation Multiples
Start free trialTwist Bioscience Financials
Twist Bioscience reported last 12-month revenue of $424M and negative EBITDA of ($38M).
In the same LTM period, Twist Bioscience generated $220M in gross profit, ($38M) in EBITDA losses, and had net loss of ($111M).
Revenue (LTM)
Twist Bioscience P&L
In the most recent fiscal year, Twist Bioscience reported revenue of $377M and EBITDA of ($47M).
Twist Bioscience is unprofitable as of last fiscal year, with gross margin of 51%, EBITDA margin of (12%), and net margin of (21%).
Financial data powered by Morningstar, Inc.
Twist Bioscience Stock Performance
Twist Bioscience has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
Twist Bioscience's stock price is $70.23.
Twist Bioscience share price increased by 5.0% in the last 30 days, and by 90.9% in the last year.
Twist Bioscience has an EPS (earnings per share) of $-1.25.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | 3.5% | 5.0% | 47.8% | 90.9% | $-1.25 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTwist Bioscience Valuation Multiples
Twist Bioscience trades at 10.1x EV/Revenue multiple, and (112.1x) EV/EBITDA.
EV / Revenue (LTM)
Twist Bioscience Financial Valuation Multiples
As of June 4, 2026, Twist Bioscience has market cap of $4B and EV of $4B.
Twist Bioscience has a P/E ratio of (39.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Twist Bioscience Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Twist Bioscience Margins & Growth Rates
Twist Bioscience grew revenue by 19% but EBITDA decreased by 27% in the last fiscal year.
In the most recent fiscal year, Twist Bioscience reported gross margin of 51%, EBITDA margin of (12%), and net margin of (21%).
Twist Bioscience Margins
Twist Bioscience Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Twist Bioscience Operational KPIs
Twist Bioscience's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
Twist Bioscience's Rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Twist Bioscience's Rule of X is 40% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Twist Bioscience Competitors
Twist Bioscience competitors include BillionToOne, Celcuity, 10x Genomics, Veracyte, GRAIL, Insight Lifetech, BGI Genomics, Wantai BioPharm, Genus and GeneDx.
Most Twist Bioscience public comparables operate across Diagnostics & Genomics, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 12.9x | 10.7x | 105.5x | 67.9x | |||
| - | 193.5x | (27.5x) | (22.0x) | |||
| 5.4x | 5.5x | 880.0x | (74.7x) | |||
| 6.6x | 6.3x | 24.0x | 23.1x | |||
| 12.2x | 11.2x | (4.8x) | (5.1x) | |||
| 29.2x | - | 131.6x | - | |||
| 3.3x | 3.3x | 42.3x | 38.6x | |||
| 22.7x | - | (320.8x) | - | |||
This data is available for Pro users. Sign up to see all Twist Bioscience competitors and their valuation data. Start Free Trial | ||||||
Twist Bioscience VC Funding History
Before going public, Twist Bioscience raised $243M in total equity funding, across 7 rounds.
Twist Bioscience Funding Rounds
Acquisitions by Twist Bioscience
Twist Bioscience has acquired 3 companies to date.
Last acquisition by Twist Bioscience was on November 22nd 2021. Twist Bioscience acquired Abveris for $190M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Twist Bioscience
| Description | Abveris is a biotechnology firm specializing in antibody discovery platforms for both reagent applications and therapeutic development. Headquartered in France with operations supporting global research, the company leverages advanced screening technologies to generate high-affinity antibodies for clients in pharmaceuticals and diagnostics. Founded to address complex target challenges, Abveris delivers custom solutions accelerating drug discovery pipelines worldwide. | iGenomX is a Boston-based genomics company developing comprehensive whole-genome sequencing for diagnosing rare genetic disorders. Its platform achieves over 99 percent coverage of known disease variants missed by exome sequencing, enabling detection of structural variants, repeat expansions, and complex rearrangements for pediatric and adult patients. | Genome Compiler is a computer-aided design platform for synthetic biology enabling collaboration and rapid biological engineering. Its tools allow biotechnology, agriculture, and pharmaceutical scientists to design, debug, and compile genetic constructs for faster bio-product development. |
| HQ Country | |||
| HQ City | Canton, OH | San Diego, CA | San Francisco, CA |
| Deal Date | 22 Nov 2021 | 30 Jun 2021 | 6 Apr 2016 |
| Valuation | $190M | $35M | undisclosed |
| EV/Revenue | |||
| EV/EBITDA | |||
This data is available for Pro users. Sign up to see all Twist Bioscience acquisitions and their M&A valuation multiples. Start Free Trial | |||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Twist Bioscience
| When was Twist Bioscience founded? | Twist Bioscience was founded in 2013. |
| Where is Twist Bioscience headquartered? | Twist Bioscience is headquartered in United States. |
| How many employees does Twist Bioscience have? | As of today, Twist Bioscience has over 979 employees. |
| Who is the CEO of Twist Bioscience? | Twist Bioscience's CEO is Emily M. Leproust. |
| Is Twist Bioscience publicly listed? | Yes, Twist Bioscience is a public company listed on Nasdaq. |
| What is the stock symbol of Twist Bioscience? | Twist Bioscience trades under TWST ticker. |
| When did Twist Bioscience go public? | Twist Bioscience went public in 2018. |
| Who are competitors of Twist Bioscience? | Twist Bioscience main competitors include BillionToOne, Celcuity, 10x Genomics, Veracyte, GRAIL, Insight Lifetech, BGI Genomics, Wantai BioPharm, Genus, GeneDx. |
| What is the current market cap of Twist Bioscience? | Twist Bioscience's current market cap is $4B. |
| What is the current revenue of Twist Bioscience? | Twist Bioscience's last 12 months revenue is $424M. |
| What is the current revenue growth of Twist Bioscience? | Twist Bioscience revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Twist Bioscience? | Current revenue multiple of Twist Bioscience is 10.1x. |
| Is Twist Bioscience profitable? | No, Twist Bioscience is not profitable. |
| What is the current EBITDA of Twist Bioscience? | Twist Bioscience has negative EBITDA and is not profitable. |
| What is Twist Bioscience's EBITDA margin? | Twist Bioscience's last 12 months EBITDA margin is (9%). |
| What is the current EV/EBITDA multiple of Twist Bioscience? | Current EBITDA multiple of Twist Bioscience is (112.1x). |
| What is the current FCF of Twist Bioscience? | Twist Bioscience's last 12 months FCF is ($72M). |
| What is Twist Bioscience's FCF margin? | Twist Bioscience's last 12 months FCF margin is (17%). |
| What is the current EV/FCF multiple of Twist Bioscience? | Current FCF multiple of Twist Bioscience is (59.4x). |
| How many companies Twist Bioscience has acquired to date? | As of June 2026, Twist Bioscience has acquired 3 companies. |
| What was the largest acquisition by Twist Bioscience? | $190M acquisition of Abveris on 22nd November 2021 was the largest M&A Twist Bioscience has done to date. |
| What companies Twist Bioscience acquired? | Twist Bioscience acquired Abveris, iGenomX, and Genome Compiler. |
| In how many companies Twist Bioscience has invested to date? | Twist Bioscience hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Twist Bioscience
Lists including Twist Bioscience
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
